


PHARMACEUTICAL 2017



SELLAS Life Sciences Group Inc. Rank 131 of 313





PHARMACEUTICAL 2017



SELLAS Life Sciences Group Inc. Rank 131 of 313

The relative strengths and weaknesses of SELLAS Life Sciences Group Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SELLAS Life Sciences Group Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 97% points. The greatest weakness of SELLAS Life Sciences Group Inc. is the variable Revenues, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is -124%, being 292% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	37,499
Cost of Goods Sold	0
Intangible Assets	5,898
Liabilities, Current	30,398
Liabilities, Non-Current	0
Other Assets	22,215
Other Compr. Net Income	0
Other Expenses	12,250
Other Liabilities	6,756
Other Net Income	8,561
Property and Equipment	199
Research and Development	19,860
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	65,811
Liabilities	37,154
Expenses	32,110
Stockholders Equity	28,657
Net Income	-23,549
Comprehensive Net Income	-23,549
Economic Capital Ratio	-124%